Nuvation Bio

NUVB

Market cap $2B

Nuvation Bio Inc. (NUVB) Q4 2025 Earnings Call Transcript

Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.11 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.

Successfully started 216 patients on IBTROZI ® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025 Entered into exclusive licensing and collaboration agreement with Eisai on January 11, 2026, for taletrectinib in Europe and additional countries outside U.S., China and Japan Published positive Phase 2 study results for safusidenib demonstrating durable responses for the treatment of grade 2 IDH1-mutant glioma Strong balance sheet with cash, cash equivalents, and marketable securities of $529.2 million as of December 31, 2025 Company to host a conference call today at 4:30 pm ET NEW YORK, March 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "We ended our transformational 2025 with a strong fourth quarter that underscored IBTROZI's rapid adoption, and we believe our medicine is becoming the new standard of care for people living with advanced ROS1+ NSCLC across treatment lines.

NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in four upcoming investor conferences, including fireside chats at two conferences.

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the fourth quarter and full year of 2025.

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol amendment to the ongoing global SIGMA study (also known as G203; NCT05303519) of safusidenib that expands it to a Phase 3 trial. SIGMA is evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-risk or high-grade IDH1-mutant astrocytoma.

Nuvation Bio earns a modest Buy at ~$5, supported by the steady adoption of IBTROZI, its lead asset, by patients and prescribers alike during the last 7 months. IBTROZI's patient starts stabilized at 3.3/day in late 2025, with revenue projections reaching ~$1B by 2030 based upon conservative assumptions. NUVB holds ~$620M in cash, sufficient to reach profitability, minimizing near-term dilution risk as rollout continues.

“Big mo” is an “eternal feature” of financial markets worldwide.

Nuvation Bio Inc. (NUVB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Nuvation Bio (NUVB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.